EQS-Adhoc: MEDICLIN raises full-year guidance for the 2024 financial year
|
EQS-Ad-hoc: MEDICLIN AG / Key word(s): Forecast/Annual Results Offenburg, 21 January 2025
MEDICLIN raises full-year guidance for the 2024 financial year MEDICLIN Aktiengesellschaft (Ticker: MED) announces that it is raising its guidance for the 2024 financial year. Instead of a Group EBIT* between EUR 33.0 and 39.0 million, MEDICLIN now expects a Group EBIT between EUR 48.0 and 54.0 million. The sales forecast for the Group was raised from -2.0 % to 0.0 % to now 1.0 % to 3.0 %. The preliminary figures for the fourth quarter and the 2024 financial year will be published on 27 February 2025. * As defined on the company's website at the following link Contact for further information: MEDICLIN Aktiengesellschaft Okenstraße 27 77652 Offenburg Ender Gülcan Head of Investor Relations and Sustainability Tel.: 0781/488-326 Fax: 0781/488-184 ender.guelcan@mediclin.de www.mediclin.de End of Inside Information
21-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | MEDICLIN AG |
| Okenstraße 27 | |
| 77652 Offenburg | |
| Germany | |
| Phone: | +49 (0)781 488-326 |
| Fax: | +49 (0)781 488-184 |
| E-mail: | ender.guelcan@mediclin.de |
| Internet: | www.mediclin.de |
| ISIN: | DE0006595101 |
| WKN: | 659510 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2071983 |
| End of Announcement | EQS News Service |
|
|
2071983 21-Jan-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 673,09 | 659,86 | 673,14 | 704,70 | 730,07 | 748,75 | 778,00 | |
| EBITDA1,2 | 93,58 | 77,50 | 85,22 | 90,92 | 98,73 | 103,77 | 115,00 | |
| EBITDA-Margin3 | 13,90 | 11,75 | 12,66 | 12,90 | 13,52 | 13,86 | 14,78 | |
| EBIT1,4 | 22,41 | 0,15 | 11,56 | 19,52 | 12,72 | 53,49 | 63,00 | |
| EBIT-Margin5 | 3,33 | 0,02 | 1,72 | 2,77 | 1,74 | 7,14 | 8,10 | |
| Net Profit (Loss)1 | 9,68 | -0,04 | 1,49 | 9,72 | -10,72 | 24,91 | 35,00 | |
| Net-Margin6 | 1,44 | -0,01 | 0,22 | 1,38 | -1,47 | 3,33 | 4,50 | |
| Cashflow1,7 | 69,59 | 118,69 | 81,97 | 34,64 | 78,00 | 50,57 | 74,00 | |
| Earnings per share8 | 0,20 | -0,19 | 0,03 | 0,20 | -0,23 | 0,52 | 0,74 | |
| Dividend per share8 | 0,05 | 0,00 | 0,00 | 0,00 | 0,00 | 0,04 | 0,04 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Mediclin | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 659510 | DE0006595101 | AG | 178,60 Mio € | 06.12.2000 | Kaufen | 8FW9FWGV+63 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 5,78 | 17,70 | 0,33 | 17,01 | 0,73 | 2,22 | 0,24 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,04 | 0,04 | 1,06% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 28.06.2026 | 04.05.2026 | 30.07.2026 | 04.11.2025 | 27.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +9,53% | +21,10% | +55,37% | +56,67% | -65,82% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
